Key Highlights

Risk & Performance

Pipeline Risk Assessment

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 35/100

Failure Rate

0.0%

0 terminated/withdrawn out of 4 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

0%

0 trials in Phase 3/4

Results Transparency

50%

2 of 4 completed trials have results

Key Signals

2 with results

Enrollment Performance

Analytics

Phase 2
3(75.0%)
Phase 1
1(25.0%)
4Total
Phase 2(3)
Phase 1(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (4)

Showing 4 of 4 trials
NCT03220048Phase 2Completed

Study Examining PrEP-001 in Healthy Subjects

Role: collaborator

NCT03338556Phase 2Completed

A Study to Examine the Duration of Effect of PrEP-001 in Healthy Subjects Challenged With HRV-16

Role: lead

NCT03296917Phase 2Completed

Study Examining PrEP-001 in Subjects With Asthma

Role: collaborator

NCT03198676Phase 1Completed

A Safety Study to Compare the Effect of Two PrEP-001 Nasal Powder Formulations on Nasal Mucosa and Serum Cytokine Production

Role: lead

All 4 trials loaded